Founded in 2019, Innorna is a platform-based company specializing in the research and development of delivery platforms for nucleic acid therapeutics. We are one of the few companies worldwide  that have mastered the underlying technology of mRNA delivery and proprietary LNP and mRNA technologies, with 34 invention patents filed globally in LNP and mRNA innovative technology platforms.

Innorna has partnered with several domestic and international pharmaceutical companies to co-develop nucleic acid drugs or license-out LNPs for nucleic acid therapeutics. Our pipelines encompass infectious diseases, oncology, rare diseases, and autoimmune diseases. Some of the products have entered the clinical phase. 

Innorna has raised over 140 million USD from reputable venture capital firms. We now have almost 200 employees, among which over 80% are R&D personnel. The senior management team are veterans with broad and extensive experience in pharmaceutical industry.

At Innorna, we value INNOVATION, INTEGRITY, EFFICIENCY, and OPENNESS. Headquartered in China, Innorna is committed to exploring the frontier of mRNA application based on platform technologies and leading the revolutionary step toward expanding the clinical application of mRNA in various therapeutic approaches to fulfill the unmet medical needs of patients worldwide!